NASDAQ:CLLS - Cellectis Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $34.67
Forecasted Upside: 119.41 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
1 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$15.80 As of 06/14/2021 01:00 AM ET

▲ +0.62 (4.08%)

1 month | 3 months | 12 months

Get New Cellectis Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CLLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLLS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$34.67

▲ +119.41% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $34.67, with a high forecast of $39.00 and a low forecast of $32.00. The average price target represents a 119.41% upside from the last price of $15.80.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Cellectis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
6/3/2021	Oppenheimer	Initiated Coverage	Buy	$33.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/1/2021	William Blair	Reiterated Rating	Buy		High	i Rating by R. Prasad at William Blair
5/27/2021	Robert W. Baird	Reiterated Rating	Buy	$39.00	High	i
5/4/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral		N/A	i
4/29/2021	Robert W. Baird	Reiterated Rating	Buy	$39.00	High	i
4/28/2021	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
3/16/2021	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$23.00 ➝ $39.00	High	i
3/8/2021	William Blair	Reiterated Rating	Outperform		High	i Rating by R. Prasad at William Blair
11/18/2020	William Blair	Reiterated Rating	Buy		Medium	i
10/15/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral		High	i Rating by Madhu Kumar at Robert W. Baird
8/19/2020	Citigroup	Upgrade	Neutral ➝ Buy	$15.00 ➝ $32.00	High	i
8/6/2020	Oppenheimer	Reiterated Rating	Buy	$33.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/7/2020	Robert W. Baird	Lower Price Target	Outperform	$28.00 ➝ $21.00	High	i Rating by Madhu Kumar at Robert W. Baird
5/11/2020	Robert W. Baird	Initiated Coverage	Outperform	$20.00	Medium	i
5/7/2020	Oppenheimer	Reiterated Rating	Buy	$35.00	High	i
3/6/2020	Citigroup	Boost Price Target	Neutral	$14.00 ➝ $16.00	Medium	i
3/6/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$15.00 ➝ $11.00	High	i
2/19/2020	BTIG Research	Boost Price Target	Buy	$37.00 ➝ $39.00	High	i
1/13/2020	William Blair	Reiterated Rating	Buy		High	i
12/16/2019	Nomura Securities	Reiterated Rating	Buy	$73.00	Low	i
8/12/2019	The Goldman Sachs Group	Set Price Target	Hold	$20.00	High	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/9/2019	BTIG Research	Initiated Coverage	Buy ➝ Buy	$37.00	High	i
5/24/2019	Citigroup	Reiterated Rating	Neutral ➝ Neutral	$22.00	Medium	i
3/13/2019	William Blair	Initiated Coverage	Outperform		Medium	i Rating by R. Prasad at William Blair
3/13/2019	Barclays	Reiterated Rating	Buy	$50.00	High	i
3/11/2019	Citigroup	Lower Price Target	Neutral	$37.00 ➝ $22.00	High	i
12/19/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$25.00	High	i
11/25/2018	Oppenheimer	Set Price Target	Buy	$44.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/16/2018	Barclays	Initiated Coverage	Overweight	$50.00	High	i
6/12/2018	Oppenheimer	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $44.00	Low	i
3/16/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		High	i
3/14/2018	Nomura Securities	Boost Price Target	Buy	$73.00	High	i
12/28/2017	Oppenheimer	Reiterated Rating	Outperform	$40.00 ➝ $40.00	Low	i
10/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$47.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
10/6/2017	SunTrust Banks	Reiterated Rating	Hold	$20.00	N/A	i
9/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$47.00	Low	i Rating by Eun Yang at Jefferies Financial Group Inc.
9/6/2017	Nomura Securities	Lower Price Target	Buy	$49.00 ➝ $43.00	Low	i
9/5/2017	SunTrust Banks	Downgrade	Buy ➝ Hold	$35.00 ➝ $20.00	High	i
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $40.00	High	i
8/25/2017	Jefferies Financial Group	Set Price Target	Buy	$47.00	High	i
6/3/2017	Oppenheimer	Reiterated Rating	Buy		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/10/2017	Oppenheimer	Set Price Target	Buy	$40.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$47.00	Low	i
3/21/2017	Oppenheimer	Reiterated Rating	Buy		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$49.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A	i
2/28/2017	Wells Fargo & Company	Initiated Coverage	Outperform ➝ Outperform		N/A	i
11/24/2016	Piper Jaffray Companies	Set Price Target	Buy	$41.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
9/14/2016	Oppenheimer	Reiterated Rating	Outperform	$65.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
9/9/2016	Jefferies Financial Group	Reiterated Rating	Buy	$47.00	N/A	i Rating by gena wang at Jefferies Financial Group Inc.
8/5/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
7/27/2016	Oppenheimer	Reiterated Rating	Outperform	$65.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/20/2016	Oppenheimer	Reiterated Rating	Buy		N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.

(Data available from 6/14/2016 forward)

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.

Today's Range

Now: $15.80

$15.48

$16.13

50 Day Range

MA: $17.04

$14.36

$20.24

52 Week Range

Now: $15.80

$14.18

$34.71

Volume

197,891 shs

Average Volume

358,803 shs

Market Capitalization

$718.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectis?

The following equities research analysts have issued reports on Cellectis in the last year: Citigroup Inc., Guggenheim, Oppenheimer Holdings Inc., Robert W. Baird, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CLLS.

What is the current price target for Cellectis?

3 Wall Street analysts have set twelve-month price targets for Cellectis in the last year. Their average twelve-month price target is $34.67, suggesting a possible upside of 119.4%. Robert W. Baird has the highest price target set, predicting CLLS will reach $39.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $32.00 for Cellectis in the next year.
View the latest price targets for CLLS.

What is the current consensus analyst rating for Cellectis?

Cellectis currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLLS will outperform the market and that investors should add to their positions of Cellectis.
View the latest ratings for CLLS.

What other companies compete with Cellectis?

Other companies that are similar to Cellectis include NanoString Technologies, Vericel, Sorrento Therapeutics, Editas Medicine, Revolution Medicines, Rubius Therapeutics, bluebird bio, Kymera Therapeutics, Instil Bio, C4 Therapeutics, Immunocore, Sangamo Therapeutics, BioAtla, Translate Bio and REGENXBIO.

How do I contact Cellectis' investor relations team?

Cellectis' physical mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company's listed phone number is 33-1-81-69-16-00 and its investor relations email address is [email protected] The official website for Cellectis is www.cellectis.com.